Company Overview of Lycera Corp.
Lycera Corp., a biopharmaceutical company, develops oral immune modulators for the treatment of patients with autoimmune diseases and cancer. Its product pipeline includes LYC-30937, an ATPase modulator for the treatment of inflammatory bowel disease; oral RORgamma agonists for diverse applications in immune-oncology; and Rho kinase inhibitors, histone deacetylase 6 inhibitors, RORgt antagonists, and collaboration targets. Lycera Corp. was founded in 2006 and is headquartered in Ann Arbor, Michigan.
2800 Plymouth Road
Ann Arbor, MI 48109
Founded in 2006
Key Executives for Lycera Corp.
Lycera Corp. Key Developments
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
To contact Lycera Corp., please visit www.lycera.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.